Skip to main content

Pharmacological Target Engagement, Validation, and In Vivo Translation

The most prevalent cause of new drug failure is lack of demonstration of target engagement and therapeutic effect. Students and early-career professionals need to acquire a basic understanding of how target engagement and validation “fits” into early drug development, techniques used, and how this allows for more complex MOA studies.

Drugs interact with living breathing physiology and can present different profiles of activity in organs of varying sensitivity; pharmacology furnishes scales of activity to turn 'descriptive data' (what we see in one experiment) to 'predictive data' (what will be seen under all conditions in vivo).

Who Should Attend
Biologists involved in drug discovery
Medicinal chemists
Pharmacology students
Academic pharmacologists

Course Benefits
Gain new insights into state-of-the-art ideas on drug targets and their association with therapeutic opportunities
Learn new tools to quantitatively assess molecular effects on drug targets
Learn how parameters from these methods can predict activity in all systems
Define new vistas around old targets to better define chemical targets for receptors

Course Topics
Systems- vs. target-based research
Target validation: eg.CCR5 HIV
Role of Knock outs
Drugging Targets, HTS, virtual screening
Drugging orphans (constitutive screening)
New chemical entities (esp. allosteric modulators)
50% efficacy failures: reasons why and ways forward
Target vs. pathway validation and biased signaling
Demonstrating target engagement in vitro
Demonstrating target engagement in vivo
Linking target engagement with therapeutic effect

Trying to Access Training? Click PURCHASE below. You will see the Member/Non-Member rate once you sign in.

$90 for SLAS Members
$150 for Non-members